CJC-1295 / Ipamorelin: Patient Information & Safety Notes
Also known as CJC1295, CJC 1295 ipamorelin, CJC/Ipamorelin
Other names: cjc1295-ipamorelin, cjc1295, cjcipamorelin
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue with a prolonged half-life. Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist. The combination is used to stimulate pulsatile growth hormone release. Neither is FDA-approved for general health or performance use.
In plain language
What CJC-1295 With Ipamorelin is used for
- Studied in research settings for effects on growth-hormone secretion
Taking this medicine
How it is administered
- Subcutaneous injection
Read before you decide
Risks and precautions
Risks and warnings
- Injection site irritation
- Nausea, insomnia
- Water retention
- Potential effects on blood glucose and insulin sensitivity
Who should not take it
- Personal or family history of cancer (growth-hormone-raising compounds precautionary)
Common questions
Patient questions
Is CJC-1295 / Ipamorelin FDA-approved?
No. Neither CJC-1295 nor ipamorelin is FDA-approved for any indication. They are research peptides whose safety and effectiveness in humans are not established.
Related medications
Explore treatment hubs
This information is educational — not medical advice.
This page is provided for general educational purposes and summarizes publicly available data from sources such as the U.S. Food & Drug Administration. It is not a substitute for the judgment of a licensed clinician and should not be used to start, stop, or change any medication. It may be incomplete or out of date, and individual circumstances vary. Always talk with your prescriber or pharmacist about your specific medications and health conditions. If you think you may have a medical emergency, call 911.
Sources & References
Learn more about where our data comes from and how we write and review medical content.